Company profile
Tempest Therapeutics, Inc.
NASDAQ: TPST · Healthcare · Biotechnology
#977 of 1,422 Healthcare companies by revenuebottom-quartile growth
EA Score
24DFH 17DQ 31GM —SS 41
v0.1 · 55/100 weight · provisional
↑ listing tenure, market scale · ↓ Piotroski F, operating margin
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$26.3M
Employees
4
as of 2026-08-23
Market cap
$16.6M
as of 2026-08-23
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$295.0k$295.0k2017
Net income-$26.3M-$26.3M2025
Operating income-$26.6M-$26.6M2025
Total assets$16.9M$16.9M2025
Liabilities$10.3M$10.3M2025
Equity$6.7M$6.7M2025
Revenue trend
FY2015 – FY2017 · USD
FY15
FY15
FY15
FY16
FY17
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Tempest Therapeutics, Inc.’s revenue?
Tempest Therapeutics, Inc. booked $295.0k in FY2017 revenue, contracting 55% year over year — slower than 83% of Healthcare companies we track, at a -8902.4% net margin.
Peers · Healthcare
Nexalin Technology, Inc.34DBioAtla, Inc.15DABVC BioPharma, Inc.41DMotus GI Holdings, Inc.——CannAmerica Brands Corp.——Hydrogen Hybrid Technologies, Inc.——Neighbors
San Mateo →Key facts
CEOMatthew Angel
SectorHealthcare
IndustryBiotechnology
HeadquartersBrisbane, CA
ExchangeNASDAQ: TPST
Employees4
IPO date2012-11-12
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.